NCT07598630 SHAPE Versus Milligan-Morgan Hemorrhoidectomy for Hemorrhoidal Disease
| NCT ID | NCT07598630 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Hemorrhoid |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2026-05-24 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2026-05-24 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be conducted at the General Surgery Department, Kasr Al-Ainy Teaching Hospital, Cairo University, on patients presenting with third- and fourth-degree hemorrhoids. Adult patients older than 18 years who fulfill the inclusion criteria and provide informed consent will be enrolled. Patients with inflammatory bowel disease, anal stenosis, colorectal malignancy, or fecal incontinence will be excluded. All patients will undergo detailed preoperative assessment including medical and surgical history, evaluation of anal symptoms, local anorectal examination, digital rectal examination, and routine laboratory investigations. Participants will be randomized into two groups: Group A will undergo Skin-Sparing Hemorrhoidectomy and PExy (SHAPE), while Group B will undergo conventional Milligan-Morgan hemorrhoidectomy. Postoperatively, oral fluids will be allowed after 2 hours and normal diet resumed as tolerated. Patients will be discharged on the first postoperative day unless otherwise indicated. Follow-up visits will assess postoperative pain, complications, and surgical outcome
Eligibility Criteria
Inclusion Criteria: * All patients with third- and fourth-degree piles, and their age greater than 18 years old Exclusion Criteria: * Patients with inflammatory bowel disease. * Patients with anal stenosis * Patients with colorectal malignancy * Patient with fecal incontinence
Contact & Investigator
Mostafa Sedky, MD
STUDY DIRECTOR
Cairo University
Frequently Asked Questions
Who can join the NCT07598630 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemorrhoid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07598630 currently recruiting?
Yes, NCT07598630 is actively recruiting participants. Contact the research team at drabdelaal90@gmail.com for enrollment information.
Where is the NCT07598630 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07598630 clinical trial?
NCT07598630 is sponsored by Cairo University. The principal investigator is Mostafa Sedky, MD at Cairo University. The trial plans to enroll 68 participants.